YAP1 and liver cancer: Therefore, we conducted this research to assess the potential therapeutic benefit of canagliflozin on CDD/DEN/TAA-induced HCC in rats and explore the role of AMPK/YAP/TAZ pathways that are known to mediate the advancement of liver cancer.